Clinical trials located in

Tübingen

Tübingen city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Tübingen, nestled in southwest Germany, is a quintessential university town, home to the prestigious Eberhard Karls University, founded in 1477. This historic city is characterized by its picturesque half-timbered houses and winding cobblestone streets. The Neckar River gracefully flows through Tübingen, with the iconic Holderlin Tower standing guard. A unique tradition is the Stocherkahnrennen, an annual punt race that showcases the city’s vibrant student life. Tübingen also played a significant role in the Reformation and boasts a rich academic and cultural heritage, making it a focal point of German intellectual and cultural life.

  • CT-EU-00120826

    Study on the use of Volixibat for the treatment of pruritus in patients with primary cholangitis (PBC)

    The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational drug called volixibat in patients with pruritus caused by primary cholangitis. The study aims to understand how volixibat affects the treatment of pruritus associated with this disease and to evaluate its possible effect on disease progression.

    Study participants will be randomly assigned to a group receiving volixibat or placebo. Volixibat will be administered as oral capsules twice daily. The main goal of the study is to measure the average change in daily pruritus scores using a special Adult Itch Reported Outcome (Adult ItchRO) questionnaire. Adult ItchRO is an 11-point scale for assessing pruritus severity, where 0 means no pruritus and 10 means the worst possible pruritus. The study will run from baseline to week 28.

    • Volixibat
    • Placebo
  • Testing Gantenerumab and Drug Combinations for Early Onset Alzheimer’s Disease in Families with Genetic Mutations

    This study focuses on Alzheimer’s disease, particularly an early onset type caused by a genetic mutation inherited dominantly. Various therapies will be tested, including Gantenerumab, Solanezumab, Etalanetug, and Lecanemab. The purpose is to assess the safety, tolerability, and effectiveness of these treatments in slowing the progression or improving markers of the disease.

    The study targets individuals who either have a mutation causing Alzheimer’s disease or are at risk of having such a mutation. Participants can be without symptoms or have mild signs of dementia. Both actual medications and placebo will be used to compare the effectiveness of the treatments.

    Gantenerumab is administered subcutaneously (under the skin) every four weeks, while Solanezumab is given through intravenous (IV) infusion every four weeks. Etalanetug and Lecanemab are also administered intravenously. The study design includes different stages, where the participants and research staff may or may not know which specific treatment the participant is receiving, depending on the mutation and the drug being tested.

    This adaptive study aims to find effective treatments by testing multiple therapies. The study will analyze biomarkers (biological markers) from imaging and body fluids and assess clinical and cognitive outcomes to see if the treatments are working on a biological and clinical level. After the main treatment phase, there is an option for participants to receive the active drug in an open-label extension phase.

    • Etalanetug
    • Gantenerumab
    • Solanezumab
    • Lecanemab
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • Study assessing the effectiveness of Tebentafusp administered alone and in combination with Pembrolizumab in the treatment of advanced melanoma

    The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The main focus was on a new experimental drug called tebentafusp, which is a special type of protein that helps the body’s immune system recognize and attack cancer cells.

    The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient – this could be another experimental drug, standard therapy, or simply supportive care.

    Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses.

    • Tebentafusp
    • Pembrolizumab
  • Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    • VAL-083
    • Troriluzole
    • VT1021
    • Paxalisib
    • Lomustine
    • Temozolomide
    • Regorafenib
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    • Volrustomig
    • Pemetrexed
    • Carboplatin
    • Pembrolizumab
    • Paclitaxel
  • Research on new medicine for advanced or metastatic lung cancer

    This study investigates a new medicine called JDQ443’s ability to combat advanced non-small cell lung cancer. It involves two groups based on their PD-L1 levels and mutations KRAS G12C. The study has two parts (called cohorts), each involving different people. The study is carried out in stages called ‘cycles’ which last for 21 days each. During the study, assessments will be conducted to evaluate the medicine’s effectiveness, and health monitoring will be implemented. This involves measuring factors such as the duration until disease progression and the length of survival post-treatment initiation.

    • Opnurasib/JDQ-443
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    • Efgartigimod/ EFG PH20 SC
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    • JNJ-81201887- new potential medication for Geographic Atrophy
    • Prednisone
    • Triamcinolone
  • Examining mometasone furoate role in treating long-lasting sinusitis

    This trial will study the effects of a drug called LYR-210 (Mometasone Furoate) on adults who have a long-term nose and sinus condition known as chronic rhinosinusitis (CRS). It focuses on the treatment’s effectiveness and safety over 24 weeks, comparing LYR-210 with a sham procedure. The study measures symptom changes, assessing impacts on nasal blockage, discharge, and facial pain. The trial is a significant step towards potentially offering relief to those suffering from persistent sinus challenges.

    • Mometasone Furoate/LYR-210
  • Study of new potential drug impact on advanced solid tumors’ cancer

    This study investigates the potential of a drug called LOXO-435 (or LY3866288) for individuals with specific types of cancer, including urinary system cancers, contingent on the presence of a particular gene change, FGFR3. The primary objectives are to assess the safety profile, identify potential side effects, and evaluate the efficacy of the drug. Participation in the study may extend for up to two and a half years or longer. Unlike a ‘blind’ study, both doctors and participants are aware of who is receiving the drug. The study comprises two parts: firstly, determining the optimal dose, and subsequently administering that amount to participants. Various groups exist within the study, including those solely receiving LOXO-435 and another group combining it with an additional drug. Assessment of the drug’s effectiveness involves monitoring changes in symptoms related to the bladder and physical function.

    • LOXO-435/LY3866288
    • Pembrolizumab
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    • Anticoagulation with heparin
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    • Ruxolitinib
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Deucravacitinib: A possible solution for active Sjögren’s Syndrome

    The study aims to evaluate the effectiveness and safety of the medication Deucravacitinib, also known as BMS-986165, in adults diagnosed with Active Sjögren’s Syndrome, a condition characterized by symptoms like dry eyes and mouth. The study is designed to understand how well Deucravacitinib can alleviate these symptoms compared to a placebo. This is done over a series of regular checks over time to monitor the improvement in symptoms and the overall safety of the medication for participants.

    Deucravacitinib will be given in two different doses to different groups of participants to determine which dose is more effective. Those on the placebo will later receive one of the doses of Deucravacitinib. The study will assess changes in various symptoms and measures of disease activity at several points during the study, providing insights into both the short-term and longer-term effects of the treatment.

    Throughout the study, participants will have their symptoms monitored and will undergo various assessments to see if there is any improvement in their condition and to check for any possible side effects from the medication. This includes checking the severity of their symptoms, overall health, and any changes in their body’s response to the treatment.

    • Deucravacitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • A clinical trial evaluating Baricitinib in young people with juvenile idiopathic arthritis

    This study focuses on systemic Juvenile Idiopathic Arthritis (sJIA) in children aged 1 to less than 18 years old. It aims to evaluate the long-term safety and efficacy of baricitinib, an oral medication. Participants will receive baricitinib daily and undergo regular assessments to monitor the drug’s effectiveness and any adverse effects. Key measures include the number of serious adverse events and the proportion of participants achieving minimal disease activity and remission. The study duration extends to at least 264 weeks, or approximately 5 years.

    • Baricitinib

See more clinical trials in other cities in Germany:

.